Morphine modulates cell proliferation through mir133b &mir128 in the neuroblastoma SH-SY5Y cell line.
Neuroblastoma is a childhood cancer with high incidence and high mortality rate. Great efforts are made to find new treatments and molecular markers for diagnosis and prognosis. miRNAs stand for novel strategies to modulate tumor growth, as they can act either as tumor suppressors or as oncogenes. Morphine is an opioid agonist widely used to treat severe and chronic pain, as for example cancer pain. Previous studies have revealed that morphine is able to modify cancer progression, by acting on proliferation or on apoptosis; however, up to date, the available results are contradictory, maybe due to the different doses used, routes of administration and model systems. While some studies show that morphine promotes cell proliferation and metastasis, other authors sustain that morphine effect is mainly antiproliferative and pro-apoptotic. In this study we aim to establish the effect of chronic opiate administration on cell proliferation in the neuroblastoma SH-SY5Y cell line. Low doses of morphine (10nM) promoted cell proliferation in undifferentiated cells and reduced the expression levels of miR133b, while higher doses (1μM) inhibited cell proliferation and correlated with decreased levels of miR133b and miR128 without triggering apoptosis. Naloxone, the classical opioid antagonist, could not fully block the effect of morphine on miR128 expression, so that the observed effect may be mediated by non-opioid mechanisms. Our results represent a further contribution to the hypothesis that a joint regulation of miRNA networks and the specific characteristics of the target tissue may determine the effect of morphine on tumor cell growth.
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Salamanca, Spain; Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Spain.
Veronica
V
Gonzalez-Nunez
Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Spain.
Jose Antonio
JA
Noriega-Prieto
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Salamanca, Spain; Instituto de Neurociencias de Castilla y León (INCyL), University of Salamanca, Spain; Instituto de Investigación Biomédica de Salamanca (IBSAL), Spain. Electronic address: requelmi@usal.es.
Raquel E
RE
Rodríguez
D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D035683:MicroRNAs / Q000502:physiology*; D009020:Morphine / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology; D009447:Neuroblastoma / Q000473:pathology
C545189:MIRN128 microRNA, human; C548234:MIRN133 microRNA, human; D035683:MicroRNAs; D009270:Naloxone; D009020:Morphine
Morphine; OPRM1; Proliferation; SH-SY5Y; miR128; miR133b